Status:
RECRUITING
Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
Luzerner Kantonsspital
Conditions:
Plantar Fasciitis
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Plantar fasciitis is the classic and most common type of heel pain. Considering the costs for health care and the temporary disability not only for work, plantar fasciitis results in a substantial (an...
Detailed Description
Background Plantar fasciitis is the classic and most common type of heel pain. Extrapolating the rate of 2 million or 0.6% of the US American population being treated for plantar fasciitis every year...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Clinical symptoms of a plantar fasciitis
- Plantar fasciitis in MRI
- Exclusion of differential diagnoses
- Symptoms more than 3 months
- Absolution of 3 months unsuccessful treatment
- Written informed consent
- Exclusion Criteria
- Active differential diagnoses
- Contraindications: pregnancy and breastfeeding, infection at injection sites, allergy against BTX-A
- Previous injections or surgery for plantar fasciitis
- Neurological diseases affecting the peripheral nervous system
Exclusion
Key Trial Info
Start Date :
July 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT02196155
Start Date
July 1 2016
End Date
December 1 2026
Last Update
December 10 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dep, of Orthopaedic Surgery, Inselspital, University of Berne
Bern, Switzerland, 3010
2
Department of Orthopaedic Surgery, Kantonsspital Lucerne
Lucerne, Switzerland, 6000